Bismuth chelate as a contrast agent for X-ray computed tomography

Autor:	Dan Wu, Qiang Zhang, Jing-ping Liu, Jijun Fu, Yin-lei Lin, Xi-Yong Yu, Yuan-ye Dang, Aiping Qin, Yugang Huang, Xiaoya Zhao, Xue-ping Lei, Lin Zhongxiao, Jun-jie Guo, Jie-xia Li, M. Chen, Songpei Li, Ling-yan Zhang, Yu Zhang
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	lcsh:Medical technology Biocompatibility Iohexol lcsh:Biotechnology Biomedical Engineering Pharmaceutical Science Medicine (miscellaneous) chemistry.chemical_element Nanoparticle Contrast Media Metal Nanoparticles Bioengineering 02 engineering and technology 010402 general chemistry Kidney 01 natural sciences Applied Microbiology and Biotechnology Bismuth Mice Iodinated contrast Pharmacokinetics In vivo lcsh:TP248.13-248.65 medicine Animals Chelation Tissue Distribution Whole Body Imaging Bismuth agent X-ray computed tomography Chemistry Research Pentetic Acid 021001 nanoscience & nanotechnology 0104 chemical sciences lcsh:R855-855.5 Molecular Medicine DTPA 0210 nano-technology Tomography X-Ray Computed Biomedical engineering medicine.drug
Zdroj:	Journal of Nanobiotechnology, Vol 18, Iss 1, Pp 1-10 (2020) Journal of Nanobiotechnology
ISSN:	1477-3155
DOI:	10.1186/s12951-020-00669-4
Popis:	Backgrounds Due to the unexpected side effects of the iodinated contrast agents, novel contrast agents for X-ray computed tomography (CT) imaging are urgently needed. Nanoparticles made by heavy metal elements are often employed, such as gold and bismuth. These nanoparticles have the advantages of long in vivo circulation time and tumor targeted ability. However, due to the long residence time in vivo, these nanoparticles may bring unexpected toxicity and, the preparation methods of these nanoparticles are complicated and time—consuming. Methods In this investigation, a small molecular bismuth chelate using diethylenetriaminepentaacetic acid (DPTA) as the chelating agent was proposed to be an ideal CT contrast agent. Results The preparation method is easy and cost—effective. Moreover, the bismuth agent show better CT imaging for kidney than iohexol in the aspect of improved CT values. Up to 500 µM, the bismuth agent show negligible toxicity to L02 cells and negligible hemolysis. And, the bismuth agent did not induce detectable morphology changes to the main organs of the mice after intravenously repeated administration at a high dose of 250 mg/kg. The pharmacokinetics of the bismuth agent follows the first—order elimination kinetics and, it has a short half—life time of 0.602 h. The rapid clearance from the body promised its excellent biocompatibility. Conclusions This bismuth agent may serve as a potential candidate for developing novel contrast agent for CT imaging in clinical applications.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71229069e7793a54a67264e8c25b7282 http://link.springer.com/article/10.1186/s12951-020-00669-4 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.